279 related articles for article (PubMed ID: 19721401)
1. Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction.
Knapp M; Baranowski M; Czarnowski D; Lisowska A; Zabielski P; Górski J; Musiał W
Med Sci Monit; 2009 Sep; 15(9):CR490-3. PubMed ID: 19721401
[TBL] [Abstract][Full Text] [Related]
2. Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction.
Knapp M; Lisowska A; Zabielski P; Musiał W; Baranowski M
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():53-61. PubMed ID: 24120760
[TBL] [Abstract][Full Text] [Related]
3. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor.
Theilmeier G; Schmidt C; Herrmann J; Keul P; Schäfers M; Herrgott I; Mersmann J; Larmann J; Hermann S; Stypmann J; Schober O; Hildebrand R; Schulz R; Heusch G; Haude M; von Wnuck Lipinski K; Herzog C; Schmitz M; Erbel R; Chun J; Levkau B
Circulation; 2006 Sep; 114(13):1403-9. PubMed ID: 16982942
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective role of sphingosine-1-phosphate.
Knapp M
J Physiol Pharmacol; 2011 Dec; 62(6):601-7. PubMed ID: 22314562
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease.
Sattler KJ; Elbasan S; Keul P; Elter-Schulz M; Bode C; Gräler MH; Bröcker-Preuss M; Budde T; Erbel R; Heusch G; Levkau B
Basic Res Cardiol; 2010 Nov; 105(6):821-32. PubMed ID: 20652276
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C.
Ikeda H; Ohkawa R; Watanabe N; Nakamura K; Kume Y; Nakagawa H; Yoshida H; Okubo S; Yokota H; Tomiya T; Inoue Y; Nishikawa T; Ohtomo N; Tanoue Y; Koike K; Yatomi Y
Clin Chim Acta; 2010 May; 411(9-10):765-70. PubMed ID: 20188085
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-phosphate signaling in the cardiovascular system.
Peters SL; Alewijnse AE
Curr Opin Pharmacol; 2007 Apr; 7(2):186-92. PubMed ID: 17280869
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent effect of aspirin on the level of sphingolipids in human blood.
Knapp M; Lisowska A; Knapp P; Baranowski M
Adv Med Sci; 2013; 58(2):274-81. PubMed ID: 24101372
[TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples.
Schmidt H; Schmidt R; Geisslinger G
Prostaglandins Other Lipid Mediat; 2006 Dec; 81(3-4):162-70. PubMed ID: 17085324
[TBL] [Abstract][Full Text] [Related]
10. Exercise increases plasma levels of sphingoid base-1 phosphates in humans.
Baranowski M; Charmas M; Długołęcka B; Górski J
Acta Physiol (Oxf); 2011 Nov; 203(3):373-80. PubMed ID: 21535416
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development.
Wendler CC; Rivkees SA
Dev Biol; 2006 Mar; 291(2):264-77. PubMed ID: 16434032
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate.
Kihara A; Mitsutake S; Mizutani Y; Igarashi Y
Prog Lipid Res; 2007 Mar; 46(2):126-44. PubMed ID: 17449104
[TBL] [Abstract][Full Text] [Related]
13. [Measurement of sphingosine 1-phosphate as a biomarker of atherosclerosis].
Kimura T; Okajima F; Murakami M
Rinsho Byori; 2007 Apr; 55(4):358-62. PubMed ID: 17511266
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of sphingosine and sphinganine in plasma of patients with type 2 diabetes.
Górska M; Dobrzyń A; Baranowski M
Med Sci Monit; 2005 Jan; 11(1):CR35-8. PubMed ID: 15614193
[TBL] [Abstract][Full Text] [Related]
15. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.
Huwiler A; Pfeilschifter J
Biochem Pharmacol; 2008 May; 75(10):1893-900. PubMed ID: 18321471
[TBL] [Abstract][Full Text] [Related]
16. Targeting sphingosine-1-phosphate signalling for cardioprotection.
Kennedy S; Kane KA; Pyne NJ; Pyne S
Curr Opin Pharmacol; 2009 Apr; 9(2):194-201. PubMed ID: 19070545
[TBL] [Abstract][Full Text] [Related]
17. Preanalytical standardization of sphingosine-1-phosphate, sphinganine-1-phosphate and sphingosine analysis in human plasma by liquid chromatography-tandem mass spectrometry.
Ceglarek U; Dittrich J; Helmschrodt C; Wagner K; Nofer JR; Thiery J; Becker S
Clin Chim Acta; 2014 Aug; 435():1-6. PubMed ID: 24768784
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of sphingosine-1-phosphate by HPLC after napthalene-2,3-dicarboxaldehyde (NDA) derivatization.
He X; Huang CL; Schuchman EH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):983-90. PubMed ID: 19285924
[TBL] [Abstract][Full Text] [Related]
19. Ultramarathon run markedly reduces plasma sphingosine-1-phosphate concentration.
Baranowski M; Górski J; Klapcinska B; Waskiewicz Z; Sadowska-Krepa E
Int J Sport Nutr Exerc Metab; 2014 Apr; 24(2):148-56. PubMed ID: 24092763
[TBL] [Abstract][Full Text] [Related]
20. UPLC-MS/MS method for analysis of sphingosine 1-phosphate in biological samples.
Cutignano A; Chiuminatto U; Petruzziello F; Vella FM; Fontana A
Prostaglandins Other Lipid Mediat; 2010 Sep; 93(1-2):25-9. PubMed ID: 20601074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
